Chronic kidney disease market set for strong growth through 2034
Market research forecasts significant expansion of the chronic kidney disease (CKD) market through 2034, estimating the seven major markets (7MM) at about USD 4.8 billion in 2024 and roughly 82 million people living with CKD. Drivers include aging populations, high diabetes and hypertension prevalence, greater demand for early detection using biomarkers like KIM-1 and NGAL, and a robust pipeline of combination and novel therapies from companies such as AstraZeneca, Boehringer Ingelheim, Disc Medicine, Amgen and others.
Why it mattersKIM-1 and NGAL biomarker adoption can expand early-detection patient pools.
Entities Mentioned
AstraZenecaBoehringer IngelheimDisc MedicineAmgen